Patents by Inventor David L. Morse
David L. Morse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041972Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: April 3, 2023Publication date: February 8, 2024Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari Pilon-Thomas, Scott Antonia
-
Publication number: 20230382819Abstract: The present disclosure provides processes for the preparation of alpha emitting radiopharmaceutical compositions, in particular DOTATATE complexes of alpha emitting radionuclides, as well as use of such prepared compositions in the treatment of cancers.Type: ApplicationFiled: October 14, 2021Publication date: November 30, 2023Inventors: David L. MORSE, Thaddeus J. WADAS, Darpan PANDYA, Narges TAFRESHI, Mikalai BUDZEVICH
-
Publication number: 20230167154Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: ApplicationFiled: January 24, 2022Publication date: June 1, 2023Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
-
Publication number: 20230144004Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.Type: ApplicationFiled: June 2, 2022Publication date: May 11, 2023Inventors: Mark L. McLaughlin, David L. Morse
-
Patent number: 11458212Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 9, 2019Date of Patent: October 4, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of the University of /ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Patent number: 11414455Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: GrantFiled: October 5, 2020Date of Patent: August 16, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDAInventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Patent number: 11230568Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: June 24, 2019Date of Patent: January 25, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNTVERSITY OF TEXAS SYSTEMInventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Publication number: 20220001038Abstract: Disclosed are anti-cancer compounds and imaging agents. More specifically, the disclosed agents target carbonic anhydrase IX and XII and their use in the treatment of cancer, in particular breast cancer. Specific compounds are those that have Formula II wherein R1 and R2 are each independently chosen from (CH2)nC?CH and, L is a linking moiety; n is 1-8; m is 0-8; each X is independently chosen from R3, OR3, NH2, NHR3, and; and each R3 is independently chosen from a detectable moiety or targeting moiety, with the proviso that R1 and R2 are not both (CH2)4C?CH.Type: ApplicationFiled: June 21, 2018Publication date: January 6, 2022Inventors: David L. Morse, Eugene A. Mash, M. Catherine Lee
-
Patent number: 11207429Abstract: Disclosed is CT or MR contrast agent which comprises a base or carrier scaffold formed of a polyhydroxol compound having a linker to which a Gd-DOTA is covalently bonded. Also disclosed is a method of screening a patient for colon cancer using a CT or MR contrast, which method comprises administering to a patient undergoing screening a compound as above described.Type: GrantFiled: May 11, 2015Date of Patent: December 28, 2021Assignee: Arizona Board of Regents on behalf of the University of ArizonaInventors: Eugene A. Mash, Parastou Foroutan, Suryakiran Navath, Robert J. Gillies, Gary V. Martinez, David L. Morse
-
Patent number: 11077212Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: August 24, 2011Date of Patent: August 3, 2021Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: David L. Morse, Robert J. Gillies, William Bradford Carter, Narges K. Tafreshi, Marilyn M. Bui, Steven A. Enkemann
-
Publication number: 20210230219Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: ApplicationFiled: October 5, 2020Publication date: July 29, 2021Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Patent number: 10793595Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: GrantFiled: October 3, 2018Date of Patent: October 6, 2020Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF SOUTH FLORIDAInventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
-
Publication number: 20200197530Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.Type: ApplicationFiled: September 30, 2019Publication date: June 25, 2020Inventors: Mark L. McLaughlin, David L. Morse
-
Publication number: 20200188472Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: October 21, 2019Publication date: June 18, 2020Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari Pilon-Thomas, Scott Antonia
-
Publication number: 20200164093Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: ApplicationFiled: September 9, 2019Publication date: May 28, 2020Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board of Regents on Behalf of The University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Publication number: 20200002376Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: ApplicationFiled: June 24, 2019Publication date: January 2, 2020Inventors: ROBERT J. GILLIES, DAVID L. MORSE, NATALIE M. BARKEY, KEVIN N. SILL, JOSEF VAGNER, NARGES K. TAFRESHI, JONATHAN L. SESSLER, CHRISTIAN PREIHS, VICTOR J. HRUBY
-
Patent number: 10449227Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: GrantFiled: June 26, 2015Date of Patent: October 22, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Mark McLaughlin, David L. Morse, Shari Pilon-Thomas, Scott Antonia
-
Patent number: 10426843Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.Type: GrantFiled: May 4, 2017Date of Patent: October 1, 2019Inventors: Mark L. McLaughlin, David L. Morse
-
Patent number: 10406248Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.Type: GrantFiled: September 5, 2012Date of Patent: September 10, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Arizona Board Of Regents on Behalf of the University of ArizonaInventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
-
Publication number: 20190263857Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.Type: ApplicationFiled: October 3, 2018Publication date: August 29, 2019Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski